The associations between coronary artery disease, and non-alcoholic fatty liver disease by computed tomography
The Egyptian Heart Journal volume 73, Article number: 96 (2021)
Non-alcoholic fatty liver disease (NAFLD) is increasing in recognition as a hepatic condition that is unrelated to significant alcoholic consumption, but has rather, been suggested to constitute cardiovascular risk (irrespective of traditional risk factors and high-risk plaque features). Both coronary artery disease and NAFLD share the same pathophysiology and metabolic profile. NAFLD can theoretically be a source/initiator for coronary artery disease (CAD). We aimed to study the association between NAFLD, CAD, the presence of high-risk plaque features, and the severity of stenosis.
We recruited 800 patients with suspected obstructive CAD and planned for coronary computed tomography angiography (CCTA), Exclusion criteria: heavy alcohol consumption; contraindications to contrast media; unevaluated coronary-artery segments; other known liver disease; and use of oral corticosteroids and/or amiodarone. Non-enhanced Computed Tomography abdomen was performed before the CCTA to detect NAFLD. To study the association between NAFLD and the presence of CAD, patients were classified as to either have, or not have CAD. The CAD group were then further studied for the presence of high-risk plaque features: napkin ring sign, Positive remodelling, Low Hounsfield unit (HU), and Spotty calcium; and their association with NAFLD. Thirty-two per cent of patients had NAFLD and 45% had CAD. A significant association between NAFLD and CAD was found (OR 4.21, 95% CI (confidence interval) (2.83–6.25), p = 0.000). In CAD patients, significant associations were present between NAFLD and high-risk plaque features: Napkin ring sign, Positive remodelling, Low HU, and Spotty calcium (OR 7.88, 95% CI (4.39–14.12), p < 0.001, OR 5.84, 95% (3.85–8.85), p < 0.001, OR 7.25, 95% CI (3.31–15.90), p < 0.001 and OR 6.66, 95% CI (3.75–11.82), p < 0.001), respectively. NAFLD was present in 39.30%, 50.00%, 20.00%, 54.50% and 100.00% of patients with CAD; and 1–24%; 25–49%; 50–69%; 7 = 0–99%, LMD (Left Main Disease) > 50% stenosis or 3V disease, and Total occlusion, respectively, p < 0.001.
NAFLD is strongly associated with CAD, high-risk plaque features and higher grade of stenosis.
Non-Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly recognized hepatic condition that encompasses a wide spectrum of liver affection ranging from simple steatosis to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. It is not essentially related to significant alcohol intake [1, 2].
Variation in the prevalence of NAFLD is found based on factors such as race, ethnicity, age, gender, geographical distribution, and the diagnostic modality used [3,4,5]. NAFLD has been firmly linked to insulin resistance, type 2 diabetes mellitus, dyslipidaemia, and metabolic syndrome, especially in patients with sedentary lifestyles, changing dietary patterns and increased obesity [2, 6]. These factors also comprise the risk profile for coronary artery disease (CAD). Both CAD and NAFLD share the same underlying pathophysiological mechanism, risk factors, lifestyle modification and treatment plans, and were therefore hypothesized to be closely related .
NAFLD is recently suggested to be an independent risk for cardiovascular diseases and is also associated with higher cardiovascular mortality .
Recent advances in the coronary CT (computed tomography) made it possible to diagnose obstructive CAD in acute and chronic conditions, with identification of high-risk plaque (positive remodelling, low CT attenuation, spotty calcium, or napkin ring sign). The presence of high-risk plaque was associated with a significantly increased risk of major adverse cardiac events . Furthermore, non-enhanced abdominal CT has been found to have a quantitative assessment for steatosis with good sensitivity and specificity .
Based on these findings, we aimed to study the association between NAFLD, the obstructive CAD, the presence of high-risk coronary plaque as depicted by CT, and the severity of stenosis in an Egyptian cohort.
Eight hundred patients with clinically suspected CAD referred to the radiology department for Coronary Computed Tomography Angiography (CCTA) were enrolled. Demographic data and medical history with special emphasis on cardiovascular risk factors (systemic arterial hypertension, diabetes mellitus, dyslipidaemia, and smoking status) were collected from all subjects. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of Radiology. A written informed consent was obtained from all participants before enrolling.
Patients presented with any of the following factors were excluded: (1) history of consumption of more than 20 g of alcohol per day; (2) contraindications to contrast media “e.g. history of reactions to any of the contrast agents, pregnancy, treatment of thyroid disease with radioactive iodine, and chronic or acutely worsening renal disease”; (3) unevaluated coronary-artery segments owing to motion artefacts or inadequate contrast medium filling; (4) other known liver diseases (carriers of the hepatitis B virus or hepatitis C virus); (5) use of oral corticosteroids and/or amiodarone that may be implicated in causing fatty liver at test time.
CT assessment of NAFLD
Two senior radiologists with over ten years of experience in abdominal CT (M.R. and M.M.) were blinded to the results of CCTA and performed measurements of hepatic and splenic CT attenuation on the non-enhanced CT scans independently.
The hepatic CT attenuation was measured by obtaining the mean of the attenuation values for three circular regions of interest with an area of at least 2 cm2 that were placed at three different hepatic levels. Areas of hepatic vascular and biliary structures were avoided. The splenic CT attenuation was calculated similarly.
NAFLD was defined as either hepatic CT attenuation minus splenic CT attenuation of less than 1 HU (Hounsfield unit), or the mean CT number ratio of liver-to-spleen parenchyma of less than 1 HU [11, 12].
CCTA analysis and high-risk coronary plaque assessment
Conventional CCTA was performed using a 64-detector row scanner (Toshiba, Aquilion TSX-101A). The images were then analysed and evaluated by two experienced senior radiologists (S.S and H.H.). The protocol followed the Society of Cardiovascular CT guidelines, which started by calculation of calcium score employing non-enhanced CT followed by contrast enhanced CCTA . Coronary segments were then evaluated for the presence of coronary atherosclerotic plaque and the presence stenosis. The severity of the stenosis was categorized based on Coronary Artery Disease Reporting and Data System (CAD-RADS) classification .
The presence of any high-risk plaque feature such as positive remodelling, spotty calcium, napkin ring sign or low CT number was reported blindly to the presence/absence of NAFLD .
Patients categorization and classification
Patients were classified into two groups; the first group were those who were diagnosed with CAD (CAD-RADS 1 or more), and the second group were those who had no CAD (CAD-RADS 0) as shown by CCTA.
Subgroup analysis of the first group regarding the severity of stenosis and the presence of high-risk plaque features was then performed.
Microsoft excel 2013 was used for data entry, and the SPSS (statistical package for social science) version 24 was used for data analysis. All collected inquiries were revised for competences and logical consistency.
Simple descriptive statistics (arithmetic mean and standard deviation) was used for the summary of normal quantitative data and frequencies used for qualitative data. The bivariate relationship was displayed in cross-tabulations, and comparison of proportions was performed using the Chi-square and Fisher’s exact tests, where appropriate. Independent T-test, one-way ANOVA (ANalysis of Variance) and post hoc tests were used to compare normally distributed quantitative data. The level of significance was set at probability (P) value < 0.05. The factors that were significantly associated with CAD and NAFLD in bivariate analysis (p < 0.05) were included in multivariate logistic regression models.
The ages of our study population ranged from 21 to 79 years with a mean of 52.46 ± 11.02 years, majority were males, and NAFLD was the most frequent clinical risk factor in the population. Ten per cent of our study subjects had calcium scores of more than 100. The frequencies of clinical risk factors for CAD are demonstrated in Table 1. Examples for patients demonstrating NAFLD and high-risk plaque features of the coronaries are depicted in Figs. 1, 2, 3, 4.
Comparison between patients with CAD and non-CAD
CAD was present in 440 (55%) subjects among the entire study group. Their demographics and risk factors of both groups are outlined in Table 2.
Regression analysis for the presence of CAD
Direct logistic regression was performed to assess the impact of several factors on the likelihood that patients would have CAD. The model contained seven independent variables: age, sex, NAFLD, Htn. (Hypertension), DM (Diabetes Mellitus), smoking & dyslipidaemia. The full model containing all factors was statistically significant, X2 (7, 800) = 185.14, p value < 0.001, indicating that the model was able to distinguish between patients with and without CAD. The model explained between 20.7% (Cox and Snell R square) and 27.6% (NagelKerke R squared) of the variance in CAD status and correctly classified 70.8% of cases. As shown in Table 3, only four of the independent variables made a unique statistically significant contribution to the model (age, sex, NAFLD & smoking). The strongest independent predictor of having CAD was NAFLD, recording an odds ratio (OR) of 4.21 and controlled for all other factors in the model.
Subgroup analysis of CAD patients
Approximately 25% of patients had significant CAD as shown by CCTA, with more than 70% coronary artery narrowing. Table 4 Calcified and noncalcified plaques were strongly associated with NAFLD among patients with CAD (OR 12, 95% (Confidence Interval) CI 5.632–25.568, p value < 0.001, OR, 95% CI 2.315, 1.571–1.067, p value 0.022).
High-risk plaque features (napkin ring sign, positive remodelling, low HU, and spotty calcium) were studied among the different clinical risk factors. NAFLD was found to be associated with an increased likelihood of having high-risk features among patients with CAD (Table 5).
Compared to patients without napkin ring sign, patients with Napkin ring sign were significantly older (57.9 ± 7.4 vs 54.63 ± 10.7 years, p value 0.001). This finding was not found with other CAD high-risk features including positive remodelling (54.6 ± 9.8 vs 55.8 ± 10.4 years, p value 0.2), low HU (55.8 ± 7.6 vs 55.2 ± 10.47 years, p value 0.608) and spotty calcium (55.4 ± 9.8 vs 55.1 ± 11.4 years, p value 0.793), There was no association found between the presence of NAFLD and a high calcium score of over 100 AU (Agatston Units) (OR 0.76, 95% CI 0.46–1.25, p value 0.279).
There was a significant difference among groups with different severity of stenosis, and NAFLD was present in 39.30%, 50.00%, 20.00%, 54.50% and 100.00% in patients with CAD and 1–24%, 25–49%, 50–69%, (70–99% stenosis, LMD (Left Main Disease) > 50% or 3 V disease), and Total occlusion, respectively, p < 0.001 (Fig. 5).
Recent increased awareness of the NAFLD deemed essential as it has been shown to correlate with other diseases, in particular atherosclerotic CAD [16, 17]. It has been suggested that NAFLD induces a systemic inflammatory response, increased oxidative stress, insulin resistance, fatty acid toxicity and endothelial dysfunction; all of which share the same pathophysiology for development of atherosclerotic CAD [3, 18, 19].
Despite being currently considered one of the leading liver diseases with an estimated prevalence of 15%-40% in the general population [3, 20], high variations in NAFLD prevalence are observed among different populations owing to several factors such as socio-economic status, ethnicity, the method of diagnosis, and reporting of the disease [7, 21].
NAFLD is usually defined as a deposition of lipid in more than 5% of the liver in the absence of enduring or recent heavy alcohol consumption (> 20gm/day), and after exclusion of other drugs and medical conditions that can enhance this phenomenon .
The prevalence of NAFLD in our study population was 32%, where the study cohort showed a male gender prevalence representing 71% of patients.
Our study is considered the largest in Egypt to examine the association between NAFLD and CAD, as it involved 800 patients. We found that there is not only a statistically significant association between CAD had NAFLD, but NAFLD was also significantly associated with the presence of a high-risk plaque feature and the grade of stenosis in patients diagnosed with CAD as detected by the CCTA. We used the CT modality unenhanced and enhanced for the diagnostic purpose for NAFLD or CAD, respectively, as it confers a one-stop-shop for the diagnosis of both diseases, respectively, with adequate diagnostic accuracy [10, 23].
In the current study, based on bivariate analysis, CAD was significantly associated with older age, male gender, NAFLD, hypertension, diabetes mellitus, smoking and dyslipidemia. However, the multivariate logistic regression analysis including the abovementioned factors, showed age, smoking and NAFLD to be the only independent risk factors for CAD.
The absence of a significant association between DM, hypertension, and dyslipidemia in the multivariate model was unanticipated, owing to the well-established relation between CAD and those major modifiable risk factors [24,25,26]. Our findings could be attributed to us being unaware of the duration and degree of control of those risk factors in our patients.
In our study, patients with NAFLD were almost four times more likely to have CAD. Moreover, high-risk plaque features were more frequently encountered in those patients. This can be explained theoretically by the fact that NAFLD represents an interplay among all other risk factors . This finding is affirmative to Puchner et al., 2015 study, which retrospectively analysed data from the Rule Out Myocardial Infarction by Cardiac Computed Tomography II (ROMICAT II) CAD arm in patients with acute coronary syndrome . However, our study was prospectively conducted and included patients with suspected acute and chronic coronary syndromes.
Ismael et al., 2020 found a similar association between NAFLD and CAD where they used the coronary angiography for coronary evaluation and FibroScan for the detection of liver steatosis tested on 100 patients .
We have found that NAFLD was significantly more common in patients with increased CAD severity. This finding was similar to what Sun & Lü, 2011 found .
We could not detect any significant association between the presence of NAFLD and a calcium score over 100 AU. In contrast to Kim et al., 2012 who found a strong relationship between NAFLD and coronary artery calcification . This can be attributed to the lower number of cases in our study who had a coronary calcium score above 100 AU (only 10% of the whole cohort) and those with high calcium score obscuring segmental interpretation of coronary stenosis were excluded.
The high prevalence of NAFLD and its strong association with the presence of CAD confers additional independent risk for CAD. NAFLD is significantly associated with advanced high-risk coronary plaque features and a higher grade of coronary stenosis.
Limitations of the study
The single-centre, cross-sectional design of our study is considered a limitation to corroborate a causal or temporal relationship between NAFLD and the development of CAD. Also, the use of unenhanced CT for diagnosis of NAFLD CT might not be as accurate for detecting mild steatosis .
Availability of data and materials
The data underlying this article are available in the digital library of radiology department Cairo University and cannot be shared publicly due to patients’ privacy and confidentiality as per hospital policy.
Analysis Of VAriance
Coronary Artery Disease
Coronary Artery Disease Reporting and Data System
Coronary Computed Tomography Angiography
Left Main Disease
Non-Alcoholic Fatty Liver Disease
- ROMICAT II:
Rule Out Myocardial Infarction by Cardiac Computed Tomography II
Statistical Package For Social Science
Anstee QM, McPherson S, Day CP (2011) How big a problem is non-alcoholic fatty liver disease? BMJ 343:d3897. https://doi.org/10.1136/bmj.d3897
Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10(6):330–344. https://doi.org/10.1038/nrgastro.2013.41
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40(6):1387–1395. https://doi.org/10.1002/hep.20466
Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10:686–690
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431
Masuoka HC, Chalasani N (2013) Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 1281(1):106–122. https://doi.org/10.1111/nyas.12016
Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 73(8):948–963. https://doi.org/10.1016/j.jacc.2018.11.050
Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM (2017) Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr 11(Suppl 1):S209-s216. https://doi.org/10.1016/j.dsx.2016.12.033
Ferencik M, Mayrhofer T, Bittner DO, Emami H, Puchner SB, Lu MT et al (2018) Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol 3(2):144–152. https://doi.org/10.1001/jamacardio.2017.4973
Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE (2018) Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 10(8):530–542. https://doi.org/10.4254/wjh.v10.i8.530
Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ et al (2010) Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. Am J Roentgenol 194(3):623–628. https://doi.org/10.2214/AJR.09.2590
Park YS, Park SH, Lee SS, Kim DY, Shin YM, Lee W et al (2011) Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology 258(3):760–766. https://doi.org/10.1148/radiol.10101233
Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK et al (2016) SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). J Cardiovasc Comput Tomogr 10(6):435–449. https://doi.org/10.1016/j.jcct.2016.10.002
Cury RC, Abbara S, Achenbach S, Agatston A, Berman DS, Budoff MJ et al (2016) CAD-RADS(TM) Coronary Artery Disease—Reporting and Data System. An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI). Endorsed by the American College of Cardiology. J Cardiovasc Comput Tomogr 10(4):269–281. https://doi.org/10.1016/j.jcct.2016.04.005
Puchner SB, Lu MT, Mayrhofer T, Liu T, Pursnani A, Ghoshhajra BB et al (2015) High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology 274(3):693–701. https://doi.org/10.1148/radiol.14140933
Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S et al (2019) Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16173104
Kumar R, Priyadarshi RN, Anand U (2020) Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol 8(1):76–86. https://doi.org/10.14218/jcth.2019.00051
Younossi ZM, Diehl AM, Ong JP (2002) Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 35(4):746–752
Wong VWS, Hui AY, Tsang SWC, Chan JLY, Tse AML, Chan KF et al (2006) Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4(9):1154–1161
Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH (2017) Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE 12(3):e0173499. https://doi.org/10.1371/journal.pone.0173499
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109
Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA et al (2017) Non-alcoholic fatty liver disease in Africa and Middle East: an attempt to predict the present and future implications on the healthcare system. Gastroenterol Res 10(5):271–279. https://doi.org/10.14740/gr913w
Lawrence DA, Oliva IB, Israel GM (2012) Detection of hepatic steatosis on contrast-enhanced CT images: diagnostic accuracy of identification of areas of presumed focal fatty sparing. Am J Roentgenol 199(1):44–47. https://doi.org/10.2214/AJR.11.7838
Fuchs FD, Whelton PK (2020) High blood pressure and cardiovascular disease. Hypertension 75(2):285–292. https://doi.org/10.1161/HYPERTENSIONAHA.119.14240
Lu S, Bao M-Y, Miao S-M, Zhang X, Jia Q-Q, Jing S-Q et al (2019) Prevalence of hypertension, diabetes, and dyslipidemia, and their additive effects on myocardial infarction and stroke: a cross-sectional study in Nanjing, China. Ann Transl Med 7(18):436–436. https://doi.org/10.21037/atm.2019.09.04
Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R et al (2020) Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis 19(1):42. https://doi.org/10.1186/s12944-020-01204-y
Ismael H, Tag-Adeen M, Abdel-Rady A, Shazly M, Hussein A (2020) Non-alcoholic fatty liver disease as a coronary heart disease severity predictor. Int J Clin Med 11(04):182
Sun L, Lü S-Z (2011) Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J 124(6):867–872
Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W et al (2012) Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56(2):605–613. https://doi.org/10.1002/hep.25593
Efe D, Aygün F (2014) Assessment of the relationship between non-alcoholic fatty liver disease and CAD using MSCT. Arq Bras Cardiol 102(1):10–18. https://doi.org/10.5935/abc.20130225
Ethics approval and consent to participate
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of Radiology, Cairo University Hospitals. A written informed consent was obtained from all participants before enrolling.
Consent for publication
All authors declare they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Saraya, S., Saraya, M., Mahmoud, M. et al. The associations between coronary artery disease, and non-alcoholic fatty liver disease by computed tomography. Egypt Heart J 73, 96 (2021). https://doi.org/10.1186/s43044-021-00222-0